6,344 Shares in Humana Inc. $HUM Acquired by Calydon Capital

Calydon Capital bought a new position in Humana Inc. (NYSE:HUM) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 6,344 shares of the insurance provider’s stock, valued at approximately $1,651,000.

Several other large investors have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Humana during the 2nd quarter valued at $32,000. Mather Group LLC. purchased a new stake in shares of Humana in the third quarter worth $34,000. AlphaCore Capital LLC purchased a new stake in shares of Humana in the second quarter worth $39,000. Private Wealth Management Group LLC boosted its stake in Humana by 47.5% during the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after buying an additional 48 shares during the period. Finally, BOKF NA boosted its stake in Humana by 4,125.0% during the third quarter. BOKF NA now owns 169 shares of the insurance provider’s stock valued at $44,000 after buying an additional 165 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Trading Up 1.0%

NYSE HUM opened at $165.38 on Friday. The stock’s 50-day simple moving average is $212.90 and its two-hundred day simple moving average is $247.87. Humana Inc. has a twelve month low of $163.60 and a twelve month high of $315.35. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $19.85 billion, a price-to-earnings ratio of 16.84, a PEG ratio of 1.77 and a beta of 0.44.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $3.54 annualized dividend and a yield of 2.1%. Humana’s dividend payout ratio is currently 36.05%.

Insider Buying and Selling

In other Humana news, insider Sanjay K. Shetty purchased 810 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were purchased at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the purchase, the insider owned 11,657 shares of the company’s stock, valued at $2,158,992.97. The trade was a 7.47% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.37% of the stock is owned by insiders.

Analyst Ratings Changes

HUM has been the topic of a number of research analyst reports. TD Cowen decreased their target price on Humana from $260.00 to $173.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Guggenheim dropped their price target on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Raymond James Financial cut their price objective on Humana from $340.00 to $230.00 and set an “outperform” rating for the company in a report on Friday, February 13th. UBS Group restated a “neutral” rating on shares of Humana in a research report on Wednesday, February 25th. Finally, Zacks Research raised shares of Humana from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 5th. Seven investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $225.48.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.